Tuesday, October 31, 2023

Acute Respiratory Distress Syndrome Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies - Windtree Therapeutics, Biomarck Pharmaceuticals

Acute Respiratory Distress Syndrome   Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies - Windtree Therapeutics, Biomarck Pharmaceuticals
DelveInsight Business Research LLP
Acute Respiratory Distress Syndrome - Pipeline Insight, 2023" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Respiratory Distress Syndrome pipeline landscape is provided which includes the disease overview and Acute Respiratory Distress Syndrome treatment guidelines.

Acute Respiratory Distress Syndrome - Pipeline Insight, 2023" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Respiratory Distress Syndrome pipeline landscape is provided which includes the disease overview and Acute Respiratory Distress Syndrome treatment guidelines.

Key Highlights Acute Respiratory Distress Syndrome Market 

  • Key Companies working in the Acute Respiratory Distress Syndrome market are Windtree Therapeutics, Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, and many others.

  • Key Therapies in Acute Respiratory Distress Syndrome are BIO-11006, MultiStem, and many others 

Acute Respiratory Distress Syndrome Overview

Acute Respiratory Distress Syndrome is a life-threatening acute lung injury commonly resulting from sepsis, trauma, and severe pulmonary infections that allows fluid to leak into the lungs. The signs and symptoms of Acute Respiratory Distress Syndrome vary in intensity, depending on its cause and severity, including severe shortness of breath, unusual rapid breathing, low blood pressure, confusion, and extreme tiredness. Along with medical history and physical examination, tests that help in diagnosis of Acute Respiratory Distress Syndrome are imaging tests, blood tests, and/or echocardiogram. Treatment options for Acute Respiratory Distress Syndrome include mechanical ventilation, fluid management, pharmacological treatment, extracorporeal lung support strategies, and other supportive measures. Gene therapy and stem cell therapy are under clinical investigation for the treatment of Acute Respiratory Distress Syndrome.

Click here to learn more about the Acute Respiratory Distress Syndrome Market Landscape

The Report Covers the Acute Respiratory Distress Syndrome Epidemiology Segmented by:

  • Acute Respiratory Distress Syndrome prevalent cases  

  • Acute Respiratory Distress Syndrome incident cases 

  • Acute Respiratory Distress Syndrome treatment cases 

  • Acute Respiratory Distress Syndrome diagnosed cases 

Acute Respiratory Distress Syndrome Market Outlook 

Despite decades of research, treatment options for ARDS are restricted. Supportive care with mechanical ventilation remains the mainstay of management. There are relatively few treatments available for Acute Respiratory Distress Syndrome.

Other treatment options, to which the patients with ARDS are generally subjected include supplemental oxygen, prone positioning, use of paralytics, fluid management, and a technique called positive end-expiratory pressure (PEEP) to help push the fluid out of air sacs. These are combined with continuing treatment of the original illness or injury. Because people with Acute Respiratory Distress Syndrome are less able to fight lung infections, they may develop bacterial pneumonia during the illness. Antibiotics are given to fight infection. Also, supportive treatment, such as intravenous fluid or food, may be needed.

Alveolar flooding and pulmonary edema formation are important pathophysiological derangements in patients with Acute Respiratory Distress Syndrome. Experimental data have shown that β2 agonists can increase sodium transport by activating β2 receptors on alveolar type I and type II cells, accelerating the resolution of pulmonary edema.

Because injury to the alveolar epithelium is a significant cause of Acute Respiratory Distress Syndrome, the acceleration of alveolar epithelial repair may assist in the resolution of pulmonary edema and lung injury. Keratinocyte growth factor (KGF) is important in alveolar epithelial repair, and experimental and human studies support the concept that KGF may be beneficial in patients with Acute Respiratory Distress Syndrome.

Key Companies Working in the Acute Respiratory Distress Syndrome Market

  • Windtree Therapeutics

  • Biomarck Pharmaceuticals

  • Athersys

  • Healios

  • Direct Biologics

  • Biohaven Pharmaceutical

And many others. 

Acute Respiratory Distress Syndrome Therapies Covered and Analyzed in the Report

  • BIO-11006

  • MultiStem

And many others   

 Learn more about the Key Companies and Emerging Therapies in the Acute Respiratory Distress Syndrome Market

 Table of Contents 

  1.  Key Insights 

  2.  Acute Respiratory Distress Syndrome Introduction 

  3.  Executive Summary of Acute Respiratory Distress Syndrome               

  4.  Disease Background and Overview

  5.  Epidemiology and patient population

  6.  Acute Respiratory Distress Syndrome Emerging Therapies

  7.  Acute Respiratory Distress Syndrome Market Outlook

  8.  Market Access and Reimbursement of Therapies

  9.  Market Drivers 

  10.  Market Barriers 

  11.  Appendix

  12.  Report Methodology

  13.  DelveInsight Capabilities

  14.  Disclaimer

Learn about the detailed offerings of the report @ Acute Respiratory Distress Syndrome Market Outlook

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email:Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services